Announced Wed, 29 Jul · 11:37 IST
Gland Pharma gets USFDA approval for Sugammadex Injection, Day 1 launch
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+3.6%1-day move
₹2434.00
prior close
₹2485.00
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.3+0.1+0.2+0.1+3.6+2.9+6.2+6.3+4.8+6.1+16.6———
Up moveDown movePending
AI summary
Gland Pharma received USFDA approval for its generic Sugammadex Injection in two strengths (200 mg/2 mL and 500 mg/5 mL single-dose vials), a generic of Merck's BRIDION used to reverse muscle relaxation during surgery. The company launched the product on Day 1 through its marketing partner. The reference brand had US sales of about USD 1.6 billion in the 12 months ending April 2026, indicating a large market opportunity.
Likely market impact
Positive: opens access to a large billion-dollar US market for a new generic, with Day 1 launch expected to drive early revenue.